Replies to post #57364 on Enzolytics Inc (ENZC)

[Timing101]

Santes... noted. But it definately says OTHER BIOCLONETICS DESIGNEES, so it may be Joseph C and GUARAV C, but it could include others . To your Point , I am sure that Charles has enough now to overshadow the ZHABILOV TRUST FUND in any case. For sure Charles also carries the Control Block on the New Series B Preferred Shares now.
--
The Disclosure showed this in the Zhabilov Trust Fund prior
*
Zhabilov Trust
Diana Zhabilov
Trustee
Shareholder Frisco, TX
50,000,000 shares of Series A Preferred 83.33%
and
412,000,000 Common Shares 50.51%
Series A
--
====================================
So as the disclosure said as of 11/30/2020
--
Quote
Business Combination Agreement with Bioclonetics Immunotherapeutics, Inc. Resulting in
Change of Control
On November 30, 2020, Enzolytics, Inc. (the “Company”) entered into a Business Combination
Agreement with Bioclonetics Immunotherapeutics, Inc., (“Bioclonetics”) a Texas Corporation
controlled by Charles S. Cotropia, the Company’s current Chief Executive Officer.
As consideration for the Business Combination, and in exchange for 100% of the issued and
outstanding stock of BioClonetics, the Company has agreed to issue a total of 204,430,000 newly
issued shares of Series B Preferred Stock to Charles S. Cotropia, and others Bioclonetics Designees
and 90,570,000 shares of newly issued Series B Preferred Stock to Harry Zhabilov, the Company’s
current Chief Financial Officer.
====================
Control Block Transfer Agreement
In addition, on November 30, 2020, the Zhabilov Trust, the Company’s Controlling Shareholder,
entered into a Control Block Transfer Agreement, under which the Zhabilov Trust has agreed to
transfer 35,100,000 shares of Series A Preferred Stock and 231,000,000 shares of Common Stock
(together the “Control Block”) to Charles S. Cotropia and other Bioclonetics Designees.
Once such share issuances and transfers are completed, Charles S. Cotropia will be the Company’s
new Control Block holder and majority shareholder, in addition to his role as Chief Executive
Officer of Enzolytics, Inc., resulting in a Change of Control.